Specific Changes:

On page OV 6, at red asterisks below, insert “Determine tumor homologous recombination deficiency (HRD) status to inform risk/benefit ratio associated with PARP inhibitor maintenance therapy.”

Rationale:

Patients whose tumors exhibit mutational or genomic indicators of homologous recombination deficiency (HRD) experience significantly longer progression-free survival on PARP inhibitor therapy than patients with no defect in the pathway.1-6 Information about potential degree of therapeutic benefit may be particularly useful in the maintenance setting where patients face a choice between continuous therapy and its associated risks, and a drug holiday. Recent data from multiple phase III studies support HRD tumor testing to inform what is a significant and increasingly common clinical decision.1-6

References


Sincerely,

Johnathan Lancaster, MD, PhD
Chief Medical Officer
Myriad Genetic Laboratories Inc.